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BACKGROUND: Despite many publications about cerebral cavernous malformations
(CCMs), controversy remains regarding diagnostic and management strategies.
OBJECTIVE: To develop guidelines for CCMmanagement.
METHODS: The Angioma Alliance (www.angioma.org), the patient support group in
the United States advocating on behalf of patients and research in CCM, convened a
multidisciplinary writing group comprising expert CCM clinicians to help summarize the
existing literature related to the clinical care of CCM, focusing on 5 topics: (1) epidemi-
ology and natural history, (2) genetic testing and counseling, (3) diagnostic criteria and
radiology standards, (4) neurosurgical considerations, and (5) neurological considerations.
The group reviewed literature, rated evidence, developed recommendations, and estab-
lished consensus, controversies, and knowledgegaps according to a prespecifiedprotocol.
RESULTS: Of 1270 publications published between January 1, 1983 and September 31,
2014, we selected 98 based on methodological criteria, and identified 38 additional recent
or relevant publications. Topic authors used these publications to summarize current
knowledge and arrive at 23 consensus management recommendations, which we rated
by class (size of effect) and level (estimate of certainty) according to the American
Heart Association/American Stroke Association criteria. No recommendation was level A
(because of the absence of randomized controlled trials), 11 (48%)were level B, and 12 (52%)
were level C. Recommendations were class I in 8 (35%), class II in 10 (43%), and class III in 5
(22%).
CONCLUSION:Current evidence supports recommendations for themanagementof CCM,
but their generally low levels and classesmandate further research to better inform clinical
practice andupdate these recommendations. The complete recommendations document,
including the criteria for selecting reference citations, a more detailed justification of the
respective recommendations, and a summary of controversies and knowledge gaps, was
similarly peer reviewed and is available on line www.angioma.org/CCMGuidelines.
KEYWORDS: Cavernous, Angioma, Malformation, Guidelines, Recommendations
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ABBREVIATIONS: CCM, cerebral cavernous malformations; CI, confidence interval; CRE, cerebral cavernous
malformation-related epilepsy; CT, computed tomography; DVA, developmental venous anomaly; FND, focal
neurological deficit;HR,hazard ratio; ICH, intracranial hemorrhage;MRC,Medical ResearchCouncil;MRI,magnetic
resonance imaging; mRS, modified Rankin score; NSAID, nonsteroidal anti-inflamatory drug; OHS, Oxford
Handicap Scale; SRS, stereotactic radiosurgery
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A remarkable number of papers focusing on the clinicalmanagement of cerebral cavernous malformations(CCMs) have been published in the peer-reviewed liter-
ature, mostly with greater recognition of the disease upon the
advent of magnetic resonance imaging (MRI). Opinions guiding
clinical practice have been expressed based on selected infor-
mation from the literature, but these have not been synthesized
into consensus recommendations for disease management based
on systematic review of all available evidence.
The Cavernoma Alliance UK, a patient support group based
in the United Kingdom commissioned a scientific advisory
panel to develop guidelines based on high-quality evidence
published before January 1st, 2011. They found few published
studies of the diagnosis and treatment of CCM of level 1 or 2
quality according to the Centre for Evidence-Based Medicine’s
2011 criteria and were therefore unable to make many specific
recommendations.1
Expert opinions have been proposed to fill the gap that exists
between research and clinical practice.2 Expert opinions on CCM
management have been assembled in 3 published monographs
to date3-5 and in a project by invited Italian experts in 2009.6
These efforts did not use a methodology of systematic literature
review.
The current project was initiated by the Angioma Alliance
(www.angioma.org), the patient support group in the United
States advocating on behalf of patients and research in CCM.
The scope and goals of this project were developed in consul-
tation between the Angioma Alliance Scientific Advisory Board
and the patient community through the Angioma Alliance Board
of Directors and committees, which developed a range of relevant
clinical questions. The project aimed to develop expert consensus
guidelines guided by a systematic analysis of the peer-reviewed
literature with regard to relevant clinical questions impacting
CCM management. It further aimed to define levels of evidence,
areas of current consensus and controversy, and knowledge gaps in
the diagnosis (imaging, genetic testing, etc.), monitoring (surveil-
lance strategies, lifestyle decisions, etc.), and treatment (medical,
surgical resection and radiosurgery) of CCM and its associated
clinical manifestations. These consensus recommendations are
intended to define recommended care options and to guide
clinical decisions in community and referral care settings, based
on the available literature and current understanding of the disease
by its leading experts. It is also hoped that these recommendations
would provide a roadmap for future clinical research based on
relevant knowledge gaps and areas of equipoise and controversy.
The process for guideline development followed recommen-
dations of the US Preventive Services Taskforce [https://www.
uspreventiveservicestaskforce.org] and the Standards for Devel-
oping Trustworthy Clinical Practice Guidelines of the U.S.
National Academy of Medicine [https://www.ncbi.nlm.nih.gov/
books/NBK209539/] with regard to multidisciplinary writing
group composition, input by the patient community, topic-
focused systematic review of the literature, prespecified method-
ology for justifying recommendations, the standardized rating of
recommendations, and a transparent process of consensus devel-
opment regarding recommendations.
METHODS
Writing Group and Development of the Project Outline
A multidisciplinary writing group (“Writing Group”) including
clinician members of the Angioma Alliance Scientific Advisory Board,
and invited experts were assembled to help summarize the existing liter-
ature related to the clinical care of CCM, focusing on 5 key topics:
(1) epidemiology and natural history, (2) genetic testing and counseling,
(3) diagnostic criteria and radiology standards, (4) neurosurgical consid-
erations, and (5) neurological considerations. For each topic, specific
questions were formulated by the writing group with input from the
Angioma Alliance patient community, and these were developed into a
proposed outline of the sections addressing the 5 key topics. These were
used to generate specific key words for the literature search (Table 1).
Members of the Writing Group were assigned to each of the 5 respective
topics (“Topic Authors”) based on their areas of expertise, each with a
lead topic author.
Systematic Literature Review and Cataloging of
Selected References
The literature searched for publications in the English language
appearing between January 1, 1983 and September 31, 2014
with key words for the condition (linked by the word “OR”):
cavernous angioma, cavernous malformation, cavernous hemangioma,
or cavernoma. Key text words for the intervention or clinical feature
(linked by the word “AND” to the key words for the condition)
prevalence, incidence, natural history, presentation, epidemiology,
genetics, genotype, phenotype, sporadic CCM, single lesion, familial
CCM, multiple lesion, spinal CCM, pregnancy, and pediatric were
searched by the AA and KD group. Imaging, MRI, computed tomog-
raphy (CT) scan, acquisition sequences, hemorrhage, bleeding, epilepsy,
seizure, headache, antithrombotic, hormone, head injury, sports,
contraindicated activities, incidental findings, surgery, craniotomy,
radiosurgery, postoperative care, therapeutics, cerebral, spinal, brainstem,
and deep were searched by IAA and TR. The key words had been selected
by theWriting Groups based on questions identified by the lay group and
scientific advisory Board (Table 1). This search yielded 1270 publications
which were screened at the abstract level, and grouped into 5 topic areas
(some articles were listed in more than 1 topic area).
In order to practically limit the number of cited papers, the broad
lists of topic-related references were then narrowed down for prefer-
ential citation using prespecified criteria detailed in the full Guidelines
document [www.angioma.org/CCMGuidelines]. In addition to the list
of references selected for preferential citation (n = 98, 17-26 per topic
area), the Topic Authors were given wide leeway in citing references from
the broader list, other and newer references (appearing after September
2014 date of systematic literature review) that they felt were critical
for articulating a specific recommendation. For topic questions without
published peer-reviewed articles, we sought book chapters that refer to
expert opinion on those topics in the 3 published textbooks on cavernous
malformations.3-5 Ultimately, 136 references were cited in support of the
recommendations.
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TABLE 1. Literature Search Terms and Topics
Literature search terms for CCM (combined with the Boolean operator “OR”)
Cavernous angioma, cavernous malformation, cavernous hemangioma, or cavernoma
Literature search terms for the topics (combined with terms for CCMwith the Boolean operator “AND”)
Prevalence, incidence, natural history, presentation, epidemiology, genetics, genotype, phenotype, sporadic CCM, single lesion, familial CCM, multiple
lesion, spinal CCM, pregnancy, pediatric, imaging, MRI, CAT scan, CT, acquisition sequences, hemorrhage, bleeding, epilepsy, seizure, headache,
antithrombotic, hormone, head injury, incidental findings, surgery, craniotomy, radiosurgery, postoperative care, therapeutics, cerebral, spinal,
brainstem, deep, hemorrhagic stroke, and stroke
Epidemiology and natural history formulated questions/topics
Disease prevalence and incidence
Comment about rarity
Relevant outcomemeasures
Bleed risk per CCM, per patient, rebleed vs first bleed
Impact of interventions
Summary of knowledge gaps and controversies
Genetic testing and counseling formulated questions/topics
Review of the genetic basis of CCM (including relative frequencies of CCM1, CCM2, and CCM3 genotypes)
Genotype/phenotype correlation and CCM3 syndrome
Genetic testing
Benefits/advantages of genetic testing
Confirming diagnosis
Family screening
Who should be tested?
Screening of children
Prenatal testing
Summary of knowledge gaps and controversies
Diagnostic criteria and radiology standards formulated questions/topics
What are the standard criteria for MRI acquisition sequences and reporting to properly diagnose CCM of the brain and/or spinal cord?
Frequency of routine/follow-up MRI
Appropriate use/caution of CAT scans
Imaging parameters for prospective studies
New technologies and novel imaging biomarkers
Summary of knowledge gaps and controversies
Neurosurgical considerations formulated questions/topics
Indications for CCM resection—surgery vs conservative management
Thresholds for surgical intervention per CCM location and rates of complication
Surgery for CCM associated with seizures
In what situations is radiosurgery preferable to CCMmicrosurgical resection?
Special considerations for radiosurgery and familial CCM
Special considerations in solitary vs multifocal CCMs, associated venous anomalies
How to manage incidental CCMs?
Summary of knowledge gaps and controversies
Neurosurgical considerations formulated questions/topics
How to manage hemorrhage in cases of single and multiple CCMs?
How to manage seizures in cases of single and multiple CCMs?
How to manage head pain in cases of single and multiple CCMs?
How to manage incidental CCM?
Recommendations for CCMmanagement during pregnancy
Special considerations for childhood onset
Influence of select medications (antithrombics, hormonal agents, etc.)
What pain medications can be safely used and for which indications?
Contraindicated activities and potential for head injury
Summary of knowledge gaps and controversies
CCM = cerebral cavernous malformation.
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TABLE 2. Definition of Classes and Levels of Evidence Used in American Heart Association/American Stroke Association Recommendations.
Table ReprintedWith Permission. Stroke.2015;46:2032-2060 C©American Heart Association, Inc.
Class I Conditions for which there is evidence for and/or general agreement that the procedure or treatment is useful and
effective
Class II Conditions for which there is conflicting evidence and/or a divergence of opinion about the usefulness/efficacy of a
procedure or treatment
Class IIa The weight of evidence or opinion is in favor of the procedure or treatment
Class IIb Usefulness/efficacy is less well established by evidence or opinion
Class III Conditions for which there is evidence and/or general agreement that the procedure or treatment is not
useful/effective and in some cases may be harmful
Therapeutic recommendations
Level of evidence A Data derived frommultiple randomized clinical trials or meta-analyses
Level of evidence B Data derived from a single randomized trial or nonrandomized studies
Level of evidence C Consensus opinion of experts, case studies, or standard of care
Diagnostic recommendations
Level of evidence A Data derived frommultiple prospective cohort studies using a reference standard applied by a masked evaluator
Level of evidence B Data derived from a single grade A study or 1 or more case-controlled studies, or studies using a reference standard
applied by an unmasked evaluator
Level of evidence C Consensus opinion of experts
Process of Manuscript Assembly and Approval
Reference lists were catalogued by the 5 key topics (some articles
were assigned to more than 1 topic), and were distributed to the
Topic Authors. The respective Topic Authors (excepting the section on
Epidemiology and Natural History) were asked to grade the quality
of evidence for class (size of effect) and level (estimate of certainty)
using the American Heart Association scoring system (Table 2).7 Authors
were tasked to summarize, within assigned manuscript length limits, the
current knowledge reflected in the literature addressing the previously
outlined topic items, justify the respective recommendations by citing
supporting evidence or lack thereof, and to identify areas of controversy
and knowledge gaps. The writing group used the Delphi technique8 to
formulate expert opinion consensus where high-level evidence is lacking.
Anonymous voting on the levels and classes of evidence was repeated 3
times, achieving agreement among all authors regarding every recom-
mendation. There was no attempt in these guidelines to assess the
potential bias in individual studies or across studies, nor the impact that
bias might have on the recommended guidelines.
Topic drafts were circulated for comments by all the Writing
Group, and these were included in revisions and manuscript assembly
conducted by AA and IAA. The assembled manuscript was circulated
for further comments and ultimate approval by all members of the
Writing Group. We herein publish a synopsis of the recommendations,
including their detailed methodology, and a list of recommendations
with their respective classes and levels of evidence, and justifying reference
citations. The complete recommendations document, including the
criteria for selecting reference citations, a more detailed justification of
the respective recommendations, and a summary of controversies and
knowledge gaps, was similarly peer reviewed and is available online
[www.angioma.org/CCMGuidelines].
EPIDEMIOLOGY ANDUNTREATED CLINICAL
COURSE
CCM is also referred to in the literature as cavernous angioma,
hemangioma, or cavernoma (Online Mendelian Inheritance in
Man #116860). Disease prevalence is estimated at 0.16%9 to
0.5%,10,11 and a population-based annual detection rate of CCM
has been estimated at 0.56 per 100 000 per year for adults
>16 years of age.12 The most common clinical manifestations
of CCM include seizures (50%), intracranial hemorrhage (ICH;
25%), and focal neurological deficits (FND) without radio-
graphic evidence of recent hemorrhage (25%).13 However, a
significant fraction of cases (20%-50%) have no symptoms and
are discovered incidentally due to widespread availability and
utilization of brain MRI.9,14
CCMs can occur in either a sporadic or familial form, and
can also appear de novo15 or after radiation therapy.16 Approx-
imately 20% of cases present with multiple CCMs,13,17 many
with a positive family history consistent with autosomal dominant
inheritance. The diagnosis of familial CCM can be confirmed by
genetic testing for mutations in 3 genes: CCM1 (KRIT1), CCM2
(MGC4607), or CCM3 (PDCD10; see genetic testing section
for more details). CCM has been reported in all race/ethnicities;
however, Hispanic-Americans from the Southwest region of the
US and northern states of Mexico have a higher prevalence of
CCM18,19 due to a founder mutation in CCM1 (Q455X or
“Common Hispanic Mutation”) that explains the majority of
cases in this ethnic group.20
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FIGURE. Annual ICH per patient-year by combined, first, or recurrent ICH. Studies are ordered by selection criteria and date. ICH rates
and 95% CI (when available) from published papers are plotted. Figure adapted and updated from Al-Shahi Salman et al,13 available at
http://www.sciencedirect.com/science/article/pii/S1474442212700042, and licensed under the Creative Commons Attribution License (CC BY).
Symptomatic ICH is the most feared complication of CCM,
and the primary reason for treating them. Previous CCM natural
history studies calculating ICH rates have reported a wide range of
frequencies, partly due to differences in definition of ICH. Thus,
CCM hemorrhage was standardized in 2008 as “requiring acute
or subacute onset symptoms (any of headache, epileptic seizure,
impaired consciousness, or new/worsened FND referable to the
anatomic location of the CCM) accompanied by radiological,
pathological, surgical, or rarely only cerebrospinal fluid evidence
of recent extra- or intralesional hemorrhage. The definition
includes neither an increase in CCM diameter without other
evidence of recent hemorrhage, nor the existence of a hemosiderin
halo.”21
The authors updated a systematic review of studies published
in 201213 that (a) included 20 or more CCM patients, (b)
presented annual hemorrhage rates per-patient year, and (c) had at
least 1 year of follow-up. Figure summarizes annual hemorrhage
rates per patient-year by combined first and recurrent hemor-
rhage,19,22-28 followed by first hemorrhage13,14,17,28-32 and then
recurrent hemorrhage.13,17,28-30,32-38 Two meta-analysis studies
have been conducted; one used aggregate data from studies,39
but the most recent used individual patient data from 7 cohorts
and report a 5-year ICH risk of 15.8% (13.7%-17.9%) overall.40
Two studies and the recent individual patient data meta-analysis
also showed that the annual risk of recurrent ICH significantly
declined over time,13,17,40 which has long-term clinical impli-
cations when weighing treatment decisions for CCM patients.
Further, the risk of first hemorrhage was very low (0.08% per
patient-year) among CCM cases identified incidentally.14
Initial CCM presentation with hemorrhage (hazard ratio [HR]
5.6, 95% confidence interval [CI] 3.2-9.7) and CCM location in
the brainstem (HR 4.4, 95% CI 2.3-8.6) are the 2 risk factors
NEUROSURGERY VOLUME 80 | NUMBER 5 | MAY 2017 | 669
AKERS ET AL
for future CCM hemorrhage that have been identified by many
individual studies, and conclusively by the individual patient data
meta-analysis.40 Patients with CCM located in the brainstem have
higher rates of hemorrhage in the untreated course (ranging from
2% to 60%, Figure).28,32,35-38,40
Other than this, female sex, CCM size, and CCM multi-
plicity have all been reported as risk factors for hemorrhage with
inconsistent results.39 Al-Holou et al11 specifically examined risk
among 56CCMcases≤25 years of age (identified by screening 14
936 records at their institution over a 12-year period), and found
comparable hemorrhage rates of 1.6% per patient-year, which
was much higher in the symptomatic group (8.0%) compared to
the incidentally discovered group (0.2%). These results suggest
that there is not an increased annual risk of bleeding in children
and younger adults with CCMwhen indirectly compared to rates
reported in older adults. However, younger age at ICH is observed
in some familial cases of CCM, and lifetime hemorrhage risk is
probably greater in younger patients.
Data available on natural history of spinal cord cavernous
malformations are sparse.41 Badhiwala et al42 recently performed
a meta-analysis of 40 studies, totaling 632 cases of intramedullary
spinal cord cavernous malformations, and reported an
annual hemorrhage rate of 2.1% (95% CI: 1.3%-3.3%).
Associated CCM occurred in 17% and family history of CCM
in 12%.42
Data across familial CCM studies generally report higher
annual ICH rates per patient-year than for sporadic cases (4.3-
6.5%, Figure).19,31 Because of multiple CCMs in familial cases,
hemorrhage rates per CCM-year are also typically reported
(0.6%-1.1% per CCM-year, Figure), 19,31,43 which are similar
to sporadic cases. For cases with repeat scans, the rate of new
CCM formation per patient-year can also be calculated, which
ranges from 0.4 to a high of 2.7 new CCMs per patient-year in
CCM3 cases,39,43 demonstrating the variable and dynamic nature
of familial CCMs.
Seizures related to CCM are thought to be induced by
recurrent microhemorrhages, resulting in surrounding blood
(hemosiderin), perilesional gliosis, and inflammation.44 There has
been only 1 study examining seizures as an endpoint in CCM.
Josephson et al45 performed a prospective population-based study
of 139 adults diagnosed with CCM and found that a 5-year risk
of first-ever seizure was 6% (95% CI: 0%-14%) in 38 CCM
patients presenting with ICH/FND and 4% (95% CI: 0%-10%)
in 57 CCM patients presenting incidentally. Among adults who
never experienced ICH/FND and presented with or developed
epilepsy, the proportion achieving 2-year seizure freedom over 5
years was 47% (95% CI: 27%-67%). Thus, adults with CCM
may have a high risk of epilepsy after first-ever seizure and roughly
half achieve 2-year seizure freedom over 5 years after an epilepsy
diagnosis.
There is no standardized tool for assessing functional outcome
in CCM studies,46 and many derivatives of the modified Rankin
score (mRS) exist, such as the Oxford Handicap Scale (OHS),
which has been used in some CCM studies.47 Li et al28 calculated
5-year complete recovery rates (final mRS scores of 0) in 331
brainstem CCM patients seen at their hospital between 1985 and
2012, and found significant reduction in recovery across groups
experiencing no hemorrhages (37%), 1 hemorrhage (18%), or
more than 1 prospective hemorrhage event (11%). Overall, the
complete recovery rate was 30.3% at 2 years, which primarily
occurred within the first 18 months after the most recent
hemorrhage. Moultrie et al47 reported clinical outcomes in
109 conservatively managed CCM patients from a prospective,
population-based study conducted in Scotland between 1999
and 2003. Poor outcome was defined as at least 2 successive
ratings of the OHS scores between 2 and 6. During 5 years
of follow-up, 37% (95% CI: 28%-46%) of the conservatively
managed group experienced poor OHS outcome. Cordonnier
et al48 reported that functional impairment from hemorrhage
is milder at initial presentation for CCM than other types of
intracranial vascular malformation.
GENETIC TESTING AND COUNSELING
The genetic basis of CCM has been established. Familial
CCM, typified by multifocal CCMs and/or a family history, is
caused by loss of function mutations in 1 of 3 genes, CCM1
(KRIT1), CCM2 (MGC4607), and CCM3 (PDCD10).49,50
The functions of these genes continue to be investigated; all are
involved in signaling networks responsible for the maintenance
of junctional integrity between neighboring vascular endothelial
cells.51,52 Biallelic somatic mutations of the same genes in CCM
endothelial cells likely contribute to CCM genesis in both
familial and sporadic CCM.53,54 Approximately 20% of cases
are estimated to be familial with autosomal dominant inher-
itance,50 although estimating risks is complicated by incom-
plete penetrance and variable presentation even within families.55
The vast majority of familial cases have multiple CCMs. The
remaining 80% of CCM cases are sporadic and present most
often with solitary CCMs, often associated with a developmental
venous anomaly (DVA) and without germline mutation of any
CCM gene.53,56 Multiple CCMs in immediate association with
a DVA and/or due to localized radiation are occasionally seen in
sporadic cases.56,57
Genetic testing of familial cases should include direct
sequencing and deletion analysis of CCM1-3.58 Following this
protocol results in a mutation detection rate of at least 75% of
all cases with multiple CCMs,54,59-61 with approximately 53%
to 65% of cases are due to mutations in CCM1, 20% in CCM2,
and 10% to 16% in CCM3.59,62-64 The majority of mutations
in CCM1-3 are loss of function mutations including nonsense,
frameshift, and splice site, leading to a premature stop codon and
an unstable mRNA. Larger deletion and duplications of multiple
exons and the entire gene have been recognized, emphasizing
the importance of screening for these types of mutations when
utilizing genetic testing.65 The inherited mutation is an inherited
risk, but not sufficient for CCM genesis. It is hypothesized that a
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“second hit” or somatic mutation is required for malformation
development and, consistent with this, a second mutation has
been described in cases where somatic tissue is tested.50,53,54
Clinical severity is highly variable, but CCM1 gene mutations
may cause the least severe clinical course, and PDCD10 (CCM3)
mutations are associated with more severe disease manifes-
tations.43,63 CCM3 mutation carriers have a greater chance
of spontaneous mutation, an increased CCM burden, and a
younger mean age of presentation, which is often associated
with clinical hemorrhage. There is also a significant association
with other manifestations including skin CCMs, scoliosis, spinal
cord cavernous malformations, cognitive disability, and benign
brain tumor including meningioma, vestibular schwannoma, and
astrocytoma.43 Genotype does not entirely explain CCM clinical
variability; investigation of possible genetic and environment
modifiers is currently underway.
Recommendations for Genetic Testing and
Counseling
1. Obtain a 3-generation family history at the time of a
new diagnosis, focusing on symptoms of headache, stroke,
abnormal MRI scan, or other neurological complication.
(class I, level C).
2. Consider genetic testing of CCM1-3 genes by Sanger
or NextGen sequencing followed by deletion/duplication
analysis, in the setting of multiple CCM without an
associated DVA or history of brain radiation or with a
positive family history. (class I, level B).
3. In the setting of a positive mutation in a proband, counsel
the individual and family about autosomal dominant
inheritance and identify at-risk individuals based on the
pedigree. Genetic testing of adult at-risk family members
can be offered; however, genetic screening of asymp-
tomatic individuals raises ethical issues that should be
taken into account. Asymptomatic individuals should be
provided information on the possible psychological conse-
quences of a positive test before they make their decision
(class I, level C).
IMAGING CCMs AND REPORTING STANDARDS
CT is insensitive for detection of small CCMs, with suggestive
but not specific findings, such as multifocal calcifications.66 CT
is widely available, and is suitable for emergent identification
of acute hematoma, mass effect, and hydrocephalus. However,
small risks do accompany use of ionizing radiation as it may
promote CCM formation, and CCM patients may need repeated
imaging.67 The suspicion of CCM on CT should be followed
by MRI.68 MRI is the imaging test of choice for detection
and characterization of CCMs, with near-perfect sensitivity and
great specificity.69,70 Other differential diagnostic considera-
tions can include hemorrhagic or calcified neoplasms, especially
hemorrhagic metastases (melanoma, renal cell, others), oligo-
dendrogliomas, and pleomorphic xanthoastrocytomas.71 The
hallmark of CCMs onMRI reflects particularly blood breakdown
products within and surrounding the CCMs.21 Gradient echo
or susceptibility sequences may reveal smaller CCMs not visible
on conventional MRI sequences, particularly in association with
familial or radiation-induced CCMs.19,72 A variety of condi-
tions, especially hypertension and cerebral amyloid angiopathy
in the elderly, can cause multifocal small hemorrhages, including
microhemorrhages only visible on gradient-based techniques,
mimicking CCMs. It is unusual (but not impossible) for large
numbers of small CCMs to occur without the presence of some
additional larger, more typical CCMs.43,57
Brain imaging should be performed as soon as possible after
the onset of clinical symptoms to demonstrate hemorrhage
or new CCM formation.7,21 A CT scan may be performed
emergently, but should be followed ideally with MRI, when
assessing clinical change in CCM patients. The role of angiog-
raphy in CCM diagnosis is limited.73 An associated DVA is
usually readily seen on contrast enhanced or susceptibility-
weighted MRI sequences.57,74
Because of the importance of detecting blood breakdown
products of varying stages, both T1-weighted and T2-weighted
sequences are important. It is critical for MRI detection of
CCMs to include susceptibility-sensitive sequences. T2-weighted
gradient-echo sequences are much more sensitive for detection
of hemosiderin than fast spin-echo sequences, and susceptibility-
weighted imaging techniques using volume acquisition, thin
slices, and postprocessing offers still greater sensitivity (first
demonstrated with susceptibility-weighted imaging, although
similar techniques such as SWAN and VenoBOLD are likely to
offer similar sensitivity).57,66,75 Sensitivity to blood breakdown
products also increases with higher field. At a minimum, MRI
for evaluation of suspected CCMs must include a gradient-based
sequence with T2 weighting or susceptibility-weighted sequences
as noted above.
T1 with gadolinium contrast is mostly useful for evalu-
ation of possible associated DVAs or capillary telangiectasias,56,76
to exclude neoplasm as differential diagnosis,71 or to detect
neoplasms in association with some forms of familial CCMs.43,58
Use of gadolinium should be carefully weighed in light of recent
recognition of gadolinium retention in the globi pallidi and
dentate nuclei in some patients, although the clinical significance
of this is not yet known77,78 and the consideration of gadolinium
administration should follow any updated current guidelines by
the United States Food and Drug Administration.79 For presur-
gical planning, other factors such as location of overlying veins
and the anticipated CCM vascularity at surgery may be important
to the surgeon and may increase the importance of gadolinium
administration.
Routine follow-up of CCMs is not well established and
is dependent upon insurance, patient preferences, and neuro-
logical and/or neurosurgical practitioner’s practice standards.
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TABLE 3. SuggestedMRI Reporting Standards for Cerebral CavernousMalformations
• Magnet field strength and pulse sequences are especially valuable to include in the report when CCMs are likely. This conveys to the informed reader
useful information about sensitivity of the study for blood breakdown products.
•When a single CCM is detected, presence or absence of an associated DVA should be noted. Several CCMs around the periphery of a DVA should still be
considered part of a single vascular complex and are consistent with sporadic (unlikely genetic) disease. Multiple hemorrhagic lesions with features of
CCMs are likely due to a genetic mutation, with or without a family history. As with other imaging findings, it is appropriate with either single or multiple
lesions to include differential diagnosis, depending on the degree of confidence in characteristic vs unusual features that would suggest alternative
possibilities.
• Signal characteristics, size, location, and unusual features are helpful to report. For larger CCMs that are generally round, a single largest diameter
measurement may be adequate; for more asymmetric CCMs, orthogonal measurements may be more appropriate. Measurements should be based on
spin echo (or fast- or turbo-spin echo) sequences to avoid the “blooming” that accompanies gradient echo sequences. Detailed descriptions are
warranted for CCMs in the brainstem and in unusual locations including spinal cord, cranial nerves, cavernous sinus, and intraventricular extension.
Evidence of possible acute or subacute hemorrhage, extralesional recent hemorrhage or perilesional edema can be important.
• Small numbers of CCMs can be described in detail. Large numbers are a challenge, but estimates (eg, “approximately 20-30 small CCMs”or “greater
than 50 in each cerebral hemisphere) are more helpful than “too numerous to count.” Especially as patient portals to the electronic medical record
becomemore common, the description of “too numerous to count”CCMs can have a dramatic psychological impact on the affected patient. It is useful
to note that the presence of multiple small CCMs, visible only on gradient echo or SWI sequences, is seen in many patients with familial CCM and does
not necessarily correlate with a worse clinical outcome. In addition, the gradient echo technique, for technical reasons, causes the CCMs to appear larger
on the MRI images than they actually are in the brain. Higher field strength may result in more CCMs to be apparent on MRI than on a study previously
performed on a lower field strength magnet, and apparent differences in numbers of CCMs must be interpreted carefully. Thinner slices and less
interslice gap also increase sensitivity.
• The discovery of a CCM on a study done for an unrelated purpose should be described. However, the clinical relevance may depend on further
historical or physical examination information. Terms such as “incidental” are therefore best used carefully and, ideally, in a clinical context.
Repeat imaging is precipitated by changes in neurological status,
in particular the development of new neurological symptoms
suggestive of CCM hemorrhage, changed or worsening epilepsy,
or changes in the neurological exam. Optimal timing and indica-
tions for surveillance or follow-up scans are currently based
primarily on clinical judgment, and relatively little evidence is
available to make recommendations.
There is no evidence to justify routine spinal imaging in
patients with brain CCMs in the absence of pain or other myelo-
pathic symptoms, especially when no intervention is recom-
mended for asymptomatic spinal cavernomas (see section on
Neurosurgical Considerations).
Advanced imaging techniques may offer advantages for specific
purposes, including functional MRI and tractography,69 quanti-
tative susceptibility mapping,80 permeability imaging using
dynamic contrast-enhanced MRI,81-83 or potential use of
Ferumoxytol.84
Recommendations Regarding Imaging
1. Brain MRI is recommended for the diagnosis and clinical
follow-up of suspected or known CCM (class I, level B
evidence).
2. Brain MRI for CCM should include gradient echo or
susceptibility-weighted sequences to establish whether
there is 1, or many, CCM (class I, level B).
3. Catheter angiography is not recommended in the evalu-
ation of CCM, unless a differential diagnosis of arteri-
ovenous malformation is being considered (class III,
level C).
4. Follow-up imaging in CCM should be considered to guide
treatment decisions or to investigate new symptoms. Brain
imaging should be performed as soon as possible after
the onset of clinical symptoms suspicious of hemorrhage.
CT may be used within 1 week of symptom onset, but
MRI should be used thereafter (ideally within 2 weeks
of symptom onset). Repeat MRI should be performed in
conjunction with new or worsened symptoms to assess for
any new CCM or new hemorrhage (class I, level C).
Reporting standards have been subjective and commonly
inconsistent. However, based on input from neurologists, neuro-
surgeons, neuroradiologists, and patients, recommendations may
be offered for consideration so as to enhance interpretation and
comparability in clinical practice (Table 3).
NEUROSURGICAL CONSIDERATIONS
Despite decades of neurosurgical experience in this field,
evidence supporting surgical resection of CCM remains
conflicting. Reviews including at least 20 symptomatic CCM
patients could not identify high-quality studies that show
dramatic benefit or harm of surgery, only a few studies showed
beneficial effects of surgical resection of CCM induced seizures,
andmost studies were deemed to be biased.47,85 A recent, nonran-
domized population-based study comparing surgical excision
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to conservative management revealed poorer outcome over the
subsequent 5 years, and higher risk of symptomatic bleeds and
focal neurological deficits in the surgical group.49 However, the
baseline health of the surgical arm was not stated and patients
more severely affected by the CCM were in the excision group.
In addition, with CCMs that have previously bled, and those in
deep and infratentorial locations behaving more aggressively,44 it
is important to weigh the risk of surgery vs the natural history
of the CCM in specific clinical scenarios and CCM locations.
Management of intracerebral and intraventricular hemorrhage
associated with CCM should follow evidence-based guidelines7
for these entities, including early blood pressure control, reversal
of coagulopathy, control of intracranial pressure, and the evacu-
ation of hemorrhages causing impending herniation or posterior
fossa mass effect.7
Case series generally advocate conservative management of
asymptomatic incidentally identified CCM.86 A recent systematic
review documented an overall risk of death or nonfatal stroke of
6% after CCM resection.85 This exceeds the analogous natural
risk (2.4% over 5 years) of a CCM that has never bled. The
same postoperative risk becomes more favorable compared to
the risk associated with recurrent ICH after a first CCM bleed
(29.5% over 5 years).85 The risk of resection varies greatly with
CCM location, and this influences surgical decisions. Resection is
generally recommended for symptomatic easily accessible CCMs
given the increased risk of rebleed after first hemorrhage, and
the low morbidity associated with surgery.87,88 Other consider-
ations are needed for CCMs involving the visual pathways,89,90
and those involving the lateral ventricle.91
Deeper CCMs located in the insula, basal ganglia, and
thalamus require a more technically cautious surgery because
of the presence of critical neuronal pathways packed in smaller
areas and the risk of injury of the small perforating arteries. In
spite of careful technique, the rate of postoperative morbidity
for these CCMs is 5% to 18%, and a mortality approaching
2%, but many patients achieving recovery from severe preoper-
ative disability.88,92 Surgery for brainstem CCMs is associated
with significant early morbidity in nearly one-half of cases,
but most patients recover over time.93,94 Technical adjuncts
including image guidance,95,96 neurophysiologic monitoring,97
and laser assisted technique98,99 are thought to improve outcome
of surgical resection strategies in eloquent areas, but there are
limited controlled studies to support specific modalities. Much of
the reported literature on surgical outcomes is from specialized
centers, and hence it may not necessarily be translated to
community settings without equivalent experience.
In the case of supratentorial noneloquent region CCMs, the
risk of new neurological sequelae is equivalent to living with the
CCM for 1 to 2 years after a first bleed.47 On the other hand,
surgery in more eloquent locations is associated with higher risk,
equivalent to living with the CCM for 5 to 10 years after a first
bleed.
Spinal CCMs pose a significant challenge, with most reports
documenting surgical outcomes similar to brainstem CCMs, and
advocating similar treatment decisions.42 There remains signif-
icant controversy about whether surgical risk is justified by the
natural history.100
Medically refractory seizures due to CCM can be safely
controlled by surgical resection.101,102 Several studies showed that
pure lesionectomy results in postoperative seizure control of 70%
to 90% in patients with sporadic seizures or those with seizure
duration less than 1 year.103,104 There is a lower chance of seizure
control after surgery in cases with longer preoperative duration
of seizures.105 As a result, some authors argue for performing
early surgery in patients who fail 1 drug therapy, even if they
do not satisfy criteria for medically refractory epilepsy due to
the CCM.102 Recent report has suggested a role for laser fiber
ablation of cavernous malformation as a potentially promising
treatment of associated epilepsy.106 Further studies are needed on
epilepsy outcome in comparison to themore established approach
of lesionectomy.
An associated DVA is thought related to CCM genesis in many
sporadic cases.107,108 There is conflicting data on resection of
DVA associated with the CCM, with most authors advocating
avoiding DVA dissection to prevent serious complications such
as edema, hemorrhage, and/or venous infarcts.94,102
Stereotactic radiosurgery (SRS) has been proposed as an alter-
native treatment for symptomatic CCM in eloquent areas.94,109
A recent meta-analysis identified 4 out of 5 studies revealing
statistically significant decline in the yearly hemorrhage rate 2
years after SRS of brainstem CCM. The mortality rate was
5.61%, 11.8% developed new focal neurological deficits,110,94
and there is ongoing debate as to whether the effects of SRS
merely reflect the CCM’s natural history.111,108 Guidelines for
SRS have been proposed by Niranjan et al112 advocating to
select patients depending on age, location, risk of hemorrhage,
risk of surgical resection, and previous hemorrhage. Radiosurgery
in brain locations considered high risk for resection may be
associated with morbidity, and may have no immediate effect
on the CCM. There is legitimate concern over whether any
radiation exposure may enhance the genesis of new CCMs in
familial cases. The SRS optimal dose to reduce hemorrhage is
not known, although there are dose prescription recommenda-
tions for safety.113
Recommendations for Surgical Treatment
1. Surgical resection is not recommended for asymptomatic
CCM, especially if located in eloquent, deep, or brainstem
areas, nor in cases with multiple asymptomatic CCMs
(class III, level B).
2. Surgical resection may be considered in solitary asymp-
tomatic CCM if easily accessible in noneloquent area,
to prevent future hemorrhage, because of psychological
burden, expensive and time-consuming follow-ups, to
facilitate lifestyle or career decisions, or in patients who
might need to be on anticoagulation (class IIb, level C).
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TABLE 4. Proposed Definitions for the Relationship of Cerebral CavernousMalformations and Epilepsya
Type Definition
Definite CRE Epilepsy in patients with at least 1 CCM and evidence of a seizure onset zone in the immediate vicinity of the CCM
Probable CRE Epilepsy in a patient with at least 1 CCM and with evidence that the epilepsy is focal and arises from same
hemisphere as the CCM
Cavernomas unrelated to epilepsy Epilepsy in a patient with at least 1 CCMwith evidence that the CCM and the epilepsy are not causally related. Eg,
patient with juvenile myoclonic epilepsy or absence epilepsy and CCM
CRE = CCM-related epilepsy.
aText reprinted from Rosenow et al.102
3. Early surgical resection of CCMcausing epilepsy should be
considered, especially when medically refractory epilepsy,
in the absence of uncertainty about CCM epileptogenicity
(class IIa, level B).
4. Surgery may be considered in symptomatic easily acces-
sible CCMs, with mortality and morbidity equivalent to
living with the CCM for about 2 years (class IIb, level B).
5. Surgical resection may be considered in deep CCMs if
symptomatic or after prior hemorrhage, with mortality
and morbidity equivalent to living with the CCM for 5-10
years (class IIb, level B).
6. After reviewing the high risks of early postoperative
mortality and morbidity and impact on quality of life, it
may be reasonable to offer surgical resection of brainstem
CCM after a second symptomatic bleed as those CCMs
might have a more aggressive course (class IIb, level B).
7. Indications for resection of brainstem CCM after a single
disabling bleed, or for spinal cavernous malformations are
weaker (class IIb, level C).
8. Radiosurgery may be considered in solitary CCMs with
previous symptomatic hemorrhage if the CCM lies in
eloquent areas that carry an unacceptable high surgical risk
(class IIb, level B).
9. Radiosurgery is not recommended for asymptomatic
CCMs, for CCMs that are surgically accessible, nor in
familial CCM because of concern about de novo CCM
genesis (class III, level C).
NEUROLOGICAL CONSIDERATIONS
Definitions for the relationship of epilepsy to the CCM have
been proposed (Table 4).102 In definite CCM-related epilepsy
(CRE), antiepileptic treatment is generally recommended.45,114
There has never been a clinical trial assessing early surgery vs
antiepileptic oral therapy. In clinical practice it is common to start
with antiepileptic medication. Surgery may be considered early
to reduce future hemorrhage risk if seizures were associated with
a hemorrhagic CCM or in patients who may not be compliant
with medications. Approximately 50% to 60% of patients will
become seizure free on medication after the first diagnosis of
CRE.45,102,115,116 Patients with a known seizure disorder should
avoid medications and activities that may lower the seizure
threshold or could potentially result in harm. In addition, patients
should follow the individual state law or other governing juris-
diction about seizures and driving.
The incidence of headache in the CCM population has been
poorly studied, but may be as high as 52%.117 In patients
meeting criteria for migraine who happen to also have a
CCM, standard migraine therapy is recommended. In very small
case series, nonsteroidal anti-inflamatory drugs (NSAIDs) were
safe, but large numbers of patients have not been prospec-
tively followed.117 With the increasing use of MRI for various
neurological symptoms, CCM may be identified incidentally.
Symptomatic hemorrhage risk in these cases is low.14 The seizure
risk in patients with incidental CCM is also low (<1% per
year),14,102 hence justifying conservative management.86
Management of CCM in Children
Approximately one-fourth of sporadic and familial CCMs
occur in pediatric age groups.59 Literature specific to pediatrics
is largely based on case reports or series publications reporting
giant CCM, or the natural history and surgical outcomes of
CCM of specific location: brainstem,28,118,119 spinal cord,120 and
basal ganglia.121 Imaging in young children (typically under age 6
years or those with developmental disability) requires sedation for
accurate results, which presents some additional risk to children.
Of special interest in pediatrics is the eventual fate of small
dot-like CCMs based on radiological features118,119,122,123 with
mean annual hemorrhage rate of 1.3%. Larger CCMs not seen
exclusively on susceptibility-weighted imaging that did not have
surgery had a higher prospective hemorrhage rate.124
Based on the response of infantile hemangiomas (a distinct
condition) to propranolol, and the treatment of diffuse or
multifocal infantile hemangiomatosis involving brain and spinal
cord, propranolol has been used clinically in cases of CCM.
Case reports and case series report limited treatment success on
pediatric and adult cases without genetic confirmation of CCM
mutations.125,126 Controlled studies of propranolol have not yet
been performed in CCM, so its use for this indication cannot be
currently recommended.
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TABLE 5. Situations that Theoretically Pose Risk to Patients With Cerebral CavernousMalformationsa
Activity Theoretical mechanism
Clinical studies or
direct evidence in
relationship to CCM
Mountain climbing
above 10 000 feet
Hypoxia results in changes of VEGF, an important factor in angiogenesis and vascular
permeability.
None
Smoking Similar to above None
Water activity Patients at risk for seizure should not swim alone as a seizure in the water could be fatal. b
Scuba diving Scuba diving is not recommended for people with seizure disorder b
Contact sports Head traumamay result in an increased risk of seizure disorder b
Strenuous exercise
(aggressive aerobic
activity, power weight
lifting)
Strenuous exercise could result in impaired venous return resulting in increased peripheral
venous pressures.
None
Other (caving, skydiving,
surfing, solo airplane
flying)
Activities that could result in potential injury should a seizure occur during that activity b
VEGF = vascular endothelial growth factor.
aModified from Berg and Vay.135
bExtrapolated from Epilepsy Foundation recommendations regarding seizures, in general.
Children may develop CCM in response to therapeutic
radiation over 300 Gy in the first decade of life and without pre-
existing sporadic or familial CCMs127,128 increasing concern from
patients receiving frequent CT scans in the first decade or dental
radiographs and in the setting of carriers of CCM mutations.
Management of CCMDuring Pregnancy
Several large series have suggested that the risk of CCM
clinical symptoms and hemorrhage rate is no different than the
nonpregnant state,27,129 although some controversy remains.130
In patients with multiple CCMs, genetic counseling may be
discussed with the patient contemplating pregnancy. In patients
with a seizure disorder due to CCM, discussion of the appropriate
antiepileptic drug to reduce teratogenic side effects and folate
supplementation should occur prior to the patient becoming
pregnant, if possible. If focal neurological deficits, an acute, severe
headache, or a flare-up in seizures occur during pregnancy, MRI
scan without contrast should be considered. If a patient has a brain
hemorrhage during pregnancy, the severity of symptoms and risk
of recurrent hemorrhage need to be weighed against the risk of
surgical intervention at that point in the pregnancy. It is generally
agreed upon that vaginal delivery is appropriate in most patients
unless there is a neurological deficit that precludes such or recent
hemorrhage.
Safety of Anticoagulation
Most studies suggest the likely safety of antiplatelet
medication,131 and a low risk of bleeding from an existing
CCM in patients placed on antithrombotic.132 We must caution
that these studies were uncontrolled, with less likely treatment
of patients with recent hemorrhage. Erdur and colleagues133
report no significant difference in symptomatic ICH and
parenchymal hemorrhage rate when comparing 9 patients with
CCM compared to 341 patients without CCM undergoing
thrombolysis for expected cerebral ischemia. The safety of
other medications including estrogens, NSAIDs, triptans, other
potential blood-thinning agents (novel anticoagulants, vitamin
E, fish oil, selective serotonin reuptake inhibitors) has not been
studied or sufficiently studied in patients with CCM to make
recommendations. And there is no data on more powerful
antiplatelet therapy and novel anticoagulants.
Physical Activity
There are some activities that pose theoretical risks in CCM
patients with134 and without associated seizures135 (Table 5).
Flemming et al131 did not find any relationship to physical activity
at the time of hemorrhage due to CCM.
Potentially Beneficial Medications
Statins have been suggested in laboratory and preclinical
studies as potential therapy for CCM, but their risk and benefit
have not been carefully evaluated. Patients with CCM should
receive statins for approved cholesterol lowering and cardiovas-
cular indications, with close monitoring of the CCMs. Statins
should not be used for the purpose of treating CCM in the
absence of evidence from clinical trials.
There is biological evidence of benefit of vitamin D in the
treatment of CCM from laboratory studies. Recent report from
Girard et al136 showed an association of vitamin D deficiency
with historically aggressive CCM disease behavior. There is no
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evidence that vitamin D supplementation prevents future CCM
disease manifestations.
Laboratory studies are identifying potential targets for pharma-
cologic therapy aimed at stabilizing CCMs or preventing CCM
genesis. These await careful clinical assessment of potential safety
and effectiveness.
Recommendations Regarding Neurological
Management
1. Antiepileptic therapy for first seizure thought to be due to
a CCM is reasonable (class I, level B).
2. Patients with familial or multifocal CCM may consider
genetic counseling prior to pregnancy (class I, level C).
3. Patients may be counseled that the risk of neurological
symptoms during pregnancy is likely not different than the
nonpregnant state (class IIa, level B).
4. MRI should be considered in patients with CCM that
develop new neurological symptoms during pregnancy
(class IIa, level C).
5. Few data are available on the risk of antithrombotic
medication use in the general population of CCM patients
(class III, level C).
6. The safety of thrombolytic therapies in patients with CCM
and concomitant cerebral ischemia is unclear (class III,
level C).
7. The influence of physical activity on CCM behavior is
largely unknown (class IIb, level C).
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T he authors provide a comprehensive review of the literature oncavernous malformations (CM). These timely guidelines provide
valuable guidance for the management of CMs. The following facts and
recommendations are worth summarizing here. The prevalence of CMs
is estimated at 0.16% to 0.5%. Up to 50% of patients are asymptomatic
and are diagnosed with CMs incidentally identified by CTs and/orMRIs.
Up to 20% of patients with CMs have multiple lesions. The 2 main
features associated with future hemorrhagic presentations are an initial
presentation with a symptomatic hemorrhage and the location of the
lesion in the brainstem. The natural history of spinal cord CMs is poorly
understood given the paucity of literature on the subject. There are
no randomized controlled trials comparing surgical resection to conser-
vative treatment of CMs. It has become apparent that CMs outside
the brainstem rarely present with catastrophic symptoms. Therefore,
most neurosurgeons currently reserve surgical treatment for increasingly
symptomatic lesions that are easily accessible. CMs in the insula, basal
ganglia, and thalamus are associated with a postoperative morbidity
of up to 18% and a mortality approaching 2%. Surgical treatment of
brainstemCMs is associated with an even higher earlymorbidity of nearly
50%. Outcomes associated with CMs in these locations should be taken
into account when considering microsurgical resection. There is contro-
versy concerning microsurgical treatment of spinal cord CMs. Control of
medically refractory seizures after CM resection is favorable, and ranges
from 70 to 90% in patients with sporadic seizure and also in those with
seizures present for less than 1 year. Practically all CMs are associated with
developmental venous anomalies (DVAs), and most neurosurgeons agree
that the DVA should not be disturbed during resection of the adjacent
CM, as it is a normal venous drainage structure. Stereotactic radiosurgery
of brainstem CMs has been shown to result in a decline in the annual rate
of hemorrhage years after treatment. With regards to pregnancy, several
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studies suggest the risk of hemorrhage or symptomatic presentation of
CMs is no different during pregnancy as compared to that of the non-
pregnant state. Most practitioners do not place restrictions on vaginal
delivery in patients with CMs. Finally, there is not much data on the
risk of treatment with antiplatelet agents or anticoagulants in patients
with CMs. In my practice, however, I do not view the presence of a
CM as a contraindication to the use of antiplatelet agents or anticoagu-
lants if medically necessary. In summary, these authors are to be congrat-
ulated for this timely and thoughtful document on the epidemiology
and management of CMs is an important contribution to the clinical
management of CMs.
Rafael J. Tamargo
Baltimore, Maryland
680 | VOLUME 80 | NUMBER 5 | MAY 2017 www.neurosurgery-online.com
